Drugs / Fast-acting insulin aspart
Fast-acting insulin aspart
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03816761 | Feb → May 2019 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03977727 | Jun 2019 → Mar 2020 | type 1 diabetes mellitus | Texas Diabetes & Endocrinology, P.A. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04620967 | Feb 2021 → Jun 2022 | type 1 diabetes mellitus | Kirsten Nørgaard | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04655690 Comparator | Nov 2020 → Nov 2021 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-09-29 | Novo Nordisk A/S | Novo Nordisks nye hurtigtvirkende måltidsinsulin, Fiasp®, godkendt i USA novonordisk.com ↗ |
| 2017-09-29 | Novo Nordisk A/S | Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved in the US novonordisk.com ↗ |
| 2017-03-29 | Novo Nordisk A/S | Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the US novonordisk.com ↗ |
| 2017-01-10 | Novo Nordisk A/S | Fiasp® (hurtigtvirkende insulin aspart) godkendt i Europa novonordisk.com ↗ |
| 2017-01-10 | Novo Nordisk A/S | Fiasp® (fast-acting insulin aspart) approved in Europe novonordisk.com ↗ |
| 2016-11-11 | Novo Nordisk A/S | Novo Nordisk receives positive opinion from the European regulatory authorities for Fiasp® (fast-acting insulin aspart) for the treatment of diabetes novonordisk.com ↗ |
| 2016-11-11 | Novo Nordisk A/S | Novo Nordisk får positiv udtalelse fra de europæiske lægemiddelmyndigheder om Fiasp® (hurtigtvirkende insulin aspart) til behandling af diabetes novonordisk.com ↗ |
| 2012-12-19 | Novo Nordisk A/S | Det sidste fase 3a-studie for IDegLira afsluttet, og FIAsp godkendt til fase 3-udvikling novonordisk.com ↗ |
| 2012-12-19 | Novo Nordisk A/S | The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development novonordisk.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fast-acting insulin aspart | “This is a single-center randomized open label active-controlled crossover trial comparing efficacy and safety of fast acting insulin aspart (FA) (FIASP®) versus insulin aspart...” PMID 33090016 ↗ Mar 2021 |
| Known as | faster aspart | “We investigated the safety of, and glucose control by, the insulin-only configuration of the iLet® bionic pancreas delivering fast-acting insulin aspart (faster aspart), using...” PMID 34146238 ↗ Jun 2021 |
| Known as | FIASP | “This is a single-center randomized open label active-controlled crossover trial comparing efficacy and safety of fast acting insulin aspart (FA) (FIASP®) versus insulin aspart...” PMID 33090016 ↗ Mar 20212“Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight” NCT04655690 ↗ “Fast-acting insulin aspart (Fiasp) in insulin pump” NCT04620967 ↗ |
| Modality | Protein / enzyme biologic | “fast-acting insulin aspart” NCT04655690 ↗ |
| Route | Subcutaneous | “continuous subcutaneous insulin infusion” NCT03977727 ↗ |